Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.
Neal D ShoreEmmanuel S AntonarakisMichael S CooksonE David CrawfordAlicia K MorgansDavid M AlbalaJason HafronRichard G HarrisDaniel SaltzsteinGordon A BrownJonathan HendersonBenjamin LowentrittJeffrey M SpierRaoul ConcepcionPublished in: The Prostate (2020)
The panel has provided recommendations for monitoring PC patients while on ADT, recognizing that PC patients will progress despite testosterone suppression and, therefore, early identification of conversion from castrate-sensitive to castration resistance is critical. Also, the requirement to both identify and mitigate side effects of ADT as well as the importance of quality of life maintenance are essential to the optimization of patient care, especially as more combinatorial therapeutic strategies with ADT continue to emerge.